SG165364A1 - Treatment of autoimmune diseases - Google Patents

Treatment of autoimmune diseases

Info

Publication number
SG165364A1
SG165364A1 SG201006580-3A SG2010065803A SG165364A1 SG 165364 A1 SG165364 A1 SG 165364A1 SG 2010065803 A SG2010065803 A SG 2010065803A SG 165364 A1 SG165364 A1 SG 165364A1
Authority
SG
Singapore
Prior art keywords
autoimmune diseases
treatment
neuritis
uveitis
methods
Prior art date
Application number
SG201006580-3A
Other languages
English (en)
Inventor
Rainer Albert
Nigel Graham Cooke
Barbara Nuesslein-Hildesheim
Sven Weiler
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of SG165364A1 publication Critical patent/SG165364A1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/661Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02Muscle relaxants, e.g. for tetanus or cramps
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
SG201006580-3A 2005-09-09 2006-09-07 Treatment of autoimmune diseases SG165364A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US71599005P 2005-09-09 2005-09-09

Publications (1)

Publication Number Publication Date
SG165364A1 true SG165364A1 (en) 2010-10-28

Family

ID=37056992

Family Applications (1)

Application Number Title Priority Date Filing Date
SG201006580-3A SG165364A1 (en) 2005-09-09 2006-09-07 Treatment of autoimmune diseases

Country Status (29)

Country Link
US (1) US20080200438A1 (ru)
EP (2) EP1926483B1 (ru)
JP (4) JP5244598B2 (ru)
KR (3) KR20140117704A (ru)
CN (1) CN101257899B (ru)
AT (1) ATE489948T1 (ru)
AU (2) AU2006289100B2 (ru)
BR (1) BRPI0615906A2 (ru)
CA (2) CA2620554C (ru)
CY (1) CY1111285T1 (ru)
DE (1) DE602006018629D1 (ru)
DK (2) DK2295049T3 (ru)
ES (2) ES2529724T3 (ru)
HK (1) HK1149906A1 (ru)
IL (2) IL189665A (ru)
JO (1) JO2655B1 (ru)
MA (1) MA29787B1 (ru)
MX (1) MX2008003170A (ru)
NO (1) NO20081727L (ru)
NZ (2) NZ588372A (ru)
PL (2) PL2295049T3 (ru)
PT (2) PT1926483E (ru)
RU (2) RU2493840C2 (ru)
SG (1) SG165364A1 (ru)
SI (2) SI2295049T1 (ru)
TN (1) TNSN08103A1 (ru)
TW (2) TWI376223B (ru)
WO (1) WO2007028821A2 (ru)
ZA (1) ZA200801694B (ru)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4917433B2 (ja) * 2004-07-16 2012-04-18 杏林製薬株式会社 効果的な医薬の使用法及び副作用発現の防御に関する方法
PT2511262T (pt) 2004-10-12 2017-03-30 Kyorin Seiyaku Kk Processo para a produção de cloridrato de 2-amino-2-[2-[4-(3- benziloxi-feniltio)-2-clorofenil[etil]-1,3-propanodiol
EP1932522B1 (en) * 2005-10-07 2012-05-23 Kyorin Pharmaceutical Co., Ltd. Therapeutic agent for liver disease containing 2-amino-1,3-propanediol derivative as active ingredient
TWI389683B (zh) * 2006-02-06 2013-03-21 Kyorin Seiyaku Kk A therapeutic agent for an inflammatory bowel disease or an inflammatory bowel disease treatment using a 2-amino-1,3-propanediol derivative as an active ingredient
RS53080B (en) * 2006-08-08 2014-06-30 Kyorin Pharmaceutical Co. Ltd. AMINOPHOSPHORIC ACID ETHAR DERIVATIVE AND S1P RECEPTOR MODULATOR CONTAINING THE SAME AS THE ACTIVE INGREDIENT
WO2008018447A1 (fr) * 2006-08-08 2008-02-14 Kyorin Pharmaceutical Co., Ltd. Dérivé d'aminoalcool et immunodépresseur le contenant en tant que principe actif
US20100093745A1 (en) * 2007-02-13 2010-04-15 Kazuhiko Kuriyama Therapeutic agent or prophylactic agent for demyelinating disease comprising amino alcohol derivative as active ingredient
TW200946105A (en) 2008-02-07 2009-11-16 Kyorin Seiyaku Kk Therapeutic agent or preventive agent for inflammatory bowel disease containing amino alcohol derivative as active ingredient
RU2505288C2 (ru) * 2008-05-20 2014-01-27 Киорин Фармасьютикал Ко., Лтд. Средства поддержания индуцированной ремиссии
KR20110049870A (ko) * 2008-08-18 2011-05-12 노파르티스 아게 탈수초성 말초 신경병증의 치료를 위한 아미노 알콜 유도체
WO2011138393A1 (en) * 2010-05-06 2011-11-10 Novartis Ag Treatment of autoimmune diseases
MX2012012925A (es) * 2010-05-06 2012-12-17 Novartis Ag Regimen de dosificacion de derivados de sulfuro de diarilo.

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5141421A (en) * 1991-12-17 1992-08-25 Carrier Corporation Nested coupling mechanism for scroll machines
DE4428835A1 (de) * 1994-08-01 1996-02-08 Schering Ag Neue 3-substituierte 3H-2,3-Benzodiazepinderivate, deren Herstellung und Verwendung als Arzneimittel
EP2030614A1 (en) * 1997-02-27 2009-03-04 Novartis AG Pharmaceutical Composition comprising 2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol and a lecithin
DE60223699T2 (de) * 2001-09-27 2008-10-30 Kyorin Pharmaceutical Co., Ltd. Diarylsulfidderivat, dessen additionssalz und immunsuppressivum
DE60235900D1 (de) * 2001-09-27 2010-05-20 Kyorin Seiyaku Kk Osuppressivum
US7482491B2 (en) * 2002-09-19 2009-01-27 Kyorin Pharmaceutical Co., Ltd. Amino alcohol derivative, addition salt thereof, and immunosuppressant
TWI376363B (en) * 2002-09-24 2012-11-11 Novartis Ag Pharmaceutical combination for treating demyelinating disease
CA2499882C (en) * 2002-09-28 2010-11-09 Mcneil-Ppc, Inc. Modified release dosage form with two cores
WO2004074297A1 (ja) * 2003-02-18 2004-09-02 Kyorin Pharmaceutical Co., Ltd. アミノホスホン酸誘導体とその付加塩及びs1p受容体調節剤
PE20130200A1 (es) * 2003-04-08 2013-03-09 Novartis Ag Composicion farmaceutica que contiene un agonista del receptor s1p y un alcohol de azucar
TW200505416A (en) * 2003-08-12 2005-02-16 Mitsubishi Pharma Corp Bi-aryl compound having immunosuppressive activity
PT1660449E (pt) * 2003-08-28 2010-01-21 Novartis Ag Derivados de aminopropanol
JP4917433B2 (ja) * 2004-07-16 2012-04-18 杏林製薬株式会社 効果的な医薬の使用法及び副作用発現の防御に関する方法
MX2007006373A (es) * 2004-11-29 2007-06-20 Novartis Ag Regimen de dosificacion de un agonista del receptor s1p.
GB0504544D0 (en) * 2005-03-04 2005-04-13 Novartis Ag Organic compounds

Also Published As

Publication number Publication date
ES2529724T3 (es) 2015-02-25
ES2357426T3 (es) 2011-04-26
HK1149906A1 (en) 2011-10-21
KR20080046231A (ko) 2008-05-26
RU2008113187A (ru) 2009-10-20
KR20140019033A (ko) 2014-02-13
RU2493840C2 (ru) 2013-09-27
US20080200438A1 (en) 2008-08-21
CA2620554C (en) 2013-12-17
WO2007028821A2 (en) 2007-03-15
WO2007028821A3 (en) 2007-05-03
TWI372620B (en) 2012-09-21
NO20081727L (no) 2008-06-06
EP2295049B1 (en) 2014-11-26
NZ566137A (en) 2011-05-27
CA2620554A1 (en) 2007-03-15
TNSN08103A1 (en) 2009-07-14
ATE489948T1 (de) 2010-12-15
AU2010224355B2 (en) 2012-03-29
TW200803829A (en) 2008-01-16
SI1926483T1 (sl) 2011-04-29
RU2424795C2 (ru) 2011-07-27
EP2295049A1 (en) 2011-03-16
EP1926483B1 (en) 2010-12-01
CY1111285T1 (el) 2015-08-05
AU2010224355A1 (en) 2010-10-14
JP6077265B2 (ja) 2017-02-08
CN101257899B (zh) 2012-10-03
AU2006289100B2 (en) 2010-07-22
NZ588372A (en) 2012-03-30
CA2820510A1 (en) 2007-03-15
JP2009507810A (ja) 2009-02-26
PT1926483E (pt) 2011-03-03
MX2008003170A (es) 2008-03-18
PL1926483T3 (pl) 2011-05-31
ZA200801694B (en) 2009-09-30
JP2017019854A (ja) 2017-01-26
RU2011111117A (ru) 2012-09-27
AU2006289100A1 (en) 2007-03-15
KR20140117704A (ko) 2014-10-07
SI2295049T1 (sl) 2015-03-31
TWI376223B (en) 2012-11-11
EP1926483A2 (en) 2008-06-04
IL233328A0 (en) 2014-08-31
JP5244598B2 (ja) 2013-07-24
IL189665A0 (en) 2008-06-05
JO2655B1 (en) 2012-06-17
MA29787B1 (fr) 2008-09-01
DK2295049T3 (en) 2015-02-23
DK1926483T3 (da) 2011-03-14
PL2295049T3 (pl) 2015-04-30
DE602006018629D1 (de) 2011-01-13
KR101476591B1 (ko) 2014-12-24
PT2295049E (pt) 2015-03-02
TW201034659A (en) 2010-10-01
IL189665A (en) 2014-07-31
KR101476451B1 (ko) 2014-12-24
CN101257899A (zh) 2008-09-03
JP2015025002A (ja) 2015-02-05
BRPI0615906A2 (pt) 2011-05-31
JP2013010802A (ja) 2013-01-17

Similar Documents

Publication Publication Date Title
SG165364A1 (en) Treatment of autoimmune diseases
TW200509892A (en) Novel aminobenzophenone compounds
SG149063A1 (en) Use of modified cyclosporins for the treatment of hcv disorders
UA90698C2 (en) Triazole substituted aminobenzophenone compounds
WO2006023651A3 (en) Extended treatment of multiple sclerosis
GB2430935A (en) Tetrapeptide analogs
HK1095749A1 (en) Novel use of peptide compounds for in production of pharmacenticals for treating central neuropathic pain
MX2008007808A (es) Analogos de rifamicina y usos de ellos.
TW200700422A (en) Compounds for inhibiting ksp kinesin activity
EP1673078A4 (en) BENZYL ETHER AND BENZYLAMINO BETA SEKRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER DISEASE
NO20072092L (no) Sulfonamidforbindelser
TW200700066A (en) Compounds for inhibiting ksp kinesin activity
WO2006078576A3 (en) Aminomethyl beta-secretase inhibitors for the treatment of alzheimer's disease
MXPA05010440A (es) Amidas del acido isoquinolina-5-sulfonico como inhibidores de la akt (proteina quinasa b).
TW200738143A (en) Use of arylanilides for seed treatment
TW200504402A (en) Antimicrobial lenses, processes to prepare them and methods of their use
MXPA06004308A (es) Isopentilcarboxanilidas para la lucha contra los microorganismos indeseables.
PT1744736E (pt) Método de tratamento de distúrbios do olho seco e uveíte
MXPA06002315A (es) Abridores de canal erg para el tratamiento de arritmias cardiacas.
UA84302C2 (ru) Изопентилкарбоксанилиды и способ борьбы с нежелательными микроорганизмами
TW200505435A (en) Treatment of ocular disorders
TW200714284A (en) Novel method
WO2004056762A3 (en) Novel aminobenzophenone compounds
TW200628453A (en) Triazole substituted aminobenzophenone compounds
CY1116051T1 (el) Θεραπεια αυτοανοσων ασθενειων